Peripheral neuropathy is the most common complication associated with diabetes mellitus. Yet, in spite of its prevalence and debilitating consequences, the pathogenesis of diabetic neuropathy remains an enigma. While hyperglycemia has been identified as the fundamental metabolic disturbance, the relationship between early metabolic events characterized by electrophysiologic abnormalities and subsequent structural changes of nerve remains unclear. Previous work has shown that hyperglycemia-induced, exaggerated polyol-pathway flux underlies a number of the biochemical and functional disorders in experimental diabetes. More recently, in nerve and muscle, polyol-pathway flux has been shown to be associated with degenerative Schwann cell changes, axonal dwindling, contractile changes and myofiber degeneration that are prevented when the key enzyme of the pathway, aldose reductase, is inhibited. How inhibition of aldose reductase, an enzyme present in Schwann cells and myofibers, can restore axonal caliber is puzzling unless exaggerated polyol pathway activity disrupts other aspects of Schwann cell and/or skeletal muscle metabolism that influence the maintenance of axonal structure and function. Ciliary neurotrophic factor (CNTF), a Schwann cell-derived neurotrophic factor implicated in neurofilament synthesis, is decreased in experimental diabetes and may represent a facto capable of influencing the maintenance of axonal structure and function. The synthesis and release of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), two neurotrophins normally localized to skeletal muscle but after nerve injury also found in proliferating Schwann cells, may also be disrupted by polyol accumulation and thus have an adverse impact on the maintenance of axonal structure and function, as well as regeneration in experimental diabetes. The overall goal of the research outlined in this proposal is to examine the possibility that hyperglycemia-induced, exaggerated polyol-pathway activity hinders the production of neurotrophic factors, thereby disrupting the maintenance of axonal function and structure and impairing the ability to respond to injury. These experiments will be conducted with two well characterized rodent models of experimental diabetes: galactose intoxication and streptozotocin diabetes. The specific objectives are organized into three broad categories: 1) the impact of hyperglycemia on the bioactivity, protein, mRNA and retrograde transport of neurotrophic factors; 2) the impact of exogenous neurotrophic factor treatment on electrophysiologic, slow axonal transport and structural abnormalities likely to result from polyol accumulation; and 3) the impact of experimental diabetes on the expression of Schwann cell-derived neurotrophic factors after crush injury and the effect of exogenous treatment on the incidence and quality of regeneration. Thus, this research proposal will integrate physiologic, biochemical, morphologic and molecular biologic techniques to determine and study the functional and structural abnormalities resulting from deficits of neurotrophic factors in experimental diabetes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS032339-02
Application #
2270441
Study Section
Pathology A Study Section (PTHA)
Project Start
1994-08-01
Project End
1998-07-31
Budget Start
1995-08-01
Budget End
1996-07-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Pathology
Type
Schools of Medicine
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Mizisin, Andrew P; Shelton, G Diane; Burgers, Monica L et al. (2002) Neurological complications associated with spontaneously occurring feline diabetes mellitus. J Neuropathol Exp Neurol 61:872-84
Rende, M; Brizi, E; Donato, R et al. (2001) Prosaposin is immunolocalized to muscle and prosaptides promote myoblast fusion and attenuate loss of muscle mass after nerve injury. Muscle Nerve 24:799-808
Kobayashi, H; Mizisin, A P (2001) Nerve growth factor and neurotrophin-3 promote chemotaxis of mouse macrophages in vitro. Neurosci Lett 305:157-60
Kobayashi, H; Mizisin, A P (2000) CNTFR alpha alone or in combination with CNTF promotes macrophage chemotaxis in vitro. Neuropeptides 34:338-47
Hiraiwa, M; Campana, W M; Mizisin, A P et al. (1999) Prosaposin: a myelinotrophic protein that promotes expression of myelin constituents and is secreted after nerve injury. Glia 26:353-60
Mizisin, A P; DiStefano, P S; Liu, X et al. (1999) Decreased accumulation of endogenous brain-derived neurotrophic factor against constricting sciatic nerve ligatures in streptozotocin-diabetic and galactose-fed rats. Neurosci Lett 263:149-52
Mizisin, A P; Calcutt, N A; Tomlinson, D R et al. (1999) Neurotrophin-3 reverses nerve conduction velocity deficits in streptozotocin-diabetic rats. J Peripher Nerv Syst 4:211-21
Dines, K C; Calcutt, N A; Nunag, K D et al. (1999) Effects of hindlimb temperature on sciatic nerve laser Doppler vascular conductance in control and streptozotocin-diabetic rats. J Neurol Sci 163:17-24
Calcutt, N A; Campana, W M; Eskeland, N L et al. (1999) Prosaposin gene expression and the efficacy of a prosaposin-derived peptide in preventing structural and functional disorders of peripheral nerve in diabetic rats. J Neuropathol Exp Neurol 58:628-36
Chesnut, R M; Gautille, T; Blunt, B A et al. (1998) Neurogenic hypotension in patients with severe head injuries. J Trauma 44:958-63;discussion 963-4

Showing the most recent 10 out of 42 publications